Kurv Yield Prem Strategy Tesla ETF (TSLP)

BATS: TSLP · Real-Time Price · USD
20.19
-0.64 (-3.07%)
Aug 29, 2025, 2:42 PM - Market open
-3.07%
Assets$21.59M
Expense Ratio1.00%
PE Ratio120.49
Shares Out1.03M
Dividend (ttm)$8.40
Dividend Yield41.61%
Ex-Dividend DateAug 6, 2025
Payout FrequencyMonthly
Payout Ratio4,859.88%
Volume13,403
Open20.94
Previous Close20.83
Day's Range20.19 - 20.94
52-Week Low15.36
52-Week High34.29
Betan/a
Holdings9
Inception DateOct 27, 2023

About TSLP

Fund Home Page

The Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.

Asset Class Equity
Category Derivative Income
Region North America
Stock Exchange BATS
Ticker Symbol TSLP
ETF Provider Kurv

Dividends

Ex-DividendAmountPay Date
Aug 6, 2025$0.450Aug 7, 2025
Jul 2, 2025$0.450Jul 3, 2025
Jun 4, 2025$0.500Jun 5, 2025
May 7, 2025$0.550May 8, 2025
Apr 2, 2025$0.550Apr 3, 2025
Mar 5, 2025$0.700Mar 6, 2025
Full Dividend History

Performance

TSLP had a total return of 33.94% in the past year, including dividends. Since the fund's inception, the average annual return has been 20.82%.

News

Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...

Other symbols: AAPYAMZPGOOPMSFYNFLP
10 months ago - Business Wire

Kurv Announces Special Distributions

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Announces Special Distributions.

Other symbols: AAPYAMZPGOOPMSFYNFLP
1 year ago - Business Wire

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...

Other symbols: AZN
1 year ago - Business Wire